QUEENDALINE NWOBODO: Open Payments
NPI 1750901955 · SEVERN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$374 in 16 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $37 · 2025 $374
Food & beverage: $374
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 4 | $95 |
| E.R. Squibb & Sons, L.L.C. | 4 | $78 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $58 |
| Neurocrine BioSciences, Inc. | 2 | $56 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $14 |
Products named: COBENFY, ABILIFY MAINTENA, CAPLYTA, INGREZZA, AUSTEDO XR, ABILIFY ASIMTUFII, INVEGA SUSTENNA, Auvelity.
Industry payments across MD — which companies pay providers there.
